And what better place to find dominant companies with decades-long growth opportunities than in healthcare? Healthcare isn't going anywhere, and it's already a multitrillion-dollar industry in America ...
Eli Lilly & Co. closed $85.37 below its 52-week high ($972.53), which the company reached on August 22nd.
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
The litigation comes as pharmacy benefit managers Express Scripts, CVS Caremark and Optum Rx have faced growing criticism over their role in high drug costs — including a recent lawsuit from the ...
Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.
Texas Attorney General Ken Paxton has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers over an alleged conspiracy to increase i ...
The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...
LEBANON, Ind. (WFFT) — Eli Lilly and Company announced another $4.5 billion investment in Lebanon’s LEAP Research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results